48
Participants
Start Date
September 30, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
June 30, 2027
Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory
lyophilized antigen for reconstitution with the adjuvant CTVad (a squalene-based nanoemulsion), at the time of use.
Placebo
adjuvant CTVad (a squalene-based nanoemulsion)
Centro de Pesquisas Clínicas (CPC) do Hospital das Clínicas (HC) da UFMG/ Filial Ebserh, Belo Horizonte
University of Sao Paulo
OTHER
Financiadora de Estudos e Projetos
OTHER
Fundação de Amparo à Pesquisa do Estado de São Paulo
OTHER_GOV
INCTV National Institute of Vaccine Science and Technology
UNKNOWN
The Ministry of Science, Technology and Innovation, Brazil
UNKNOWN
CT Vacinas - Centro de Tecnologia em Vacinas/Universidade Federal de Minas Gerais
UNKNOWN
Federal University of Minas Gerais
OTHER